Skip to Content

Almirall

Mergers & Acquisitions

In addition to our licensing strategy, Almirall has an active mergers & acquisitions programme.

Our Corporate Development department looks to strengthen our international presence, contributing value to the company by means of:

  • Commercial collaborations on products currently on the market.
  • Acquisition of synergistic products with our business focus.
  • Acquisition of companies that reinforce our current structure and product portfolio.


Therapeutic Focus

Almirall's M&A programme mainly focuses on the following therapeutic areas:

  • Dermatology – where Almirall is positioned as one of the leading companies thanks to the acquisition of Hermal and a portfolio of products from Shire.
  • Spasticity in MS – where Almirall is consolidating its competitive position through the launch of Sativex.
  • Allergy – with a broad coverage of the commercial target. Our main product in this area is the anti-allergic ebastine.


Almirall also markets other innovative drugs locally in markets where we have a commercial structure. To reinforce our presence in these areas, we are interested in the acquisition of products and commercial partnerships that tie in with our local interests.